ment of multiple organ systems, and the patients are generally older than those who have the classical pneumonia. Sequelae from the CNS and the heart belong to the most serious complications [8, 9] .
Complications may also arise within the respiratory tract, such as fulminant lobar pneumonia mimicking severe bacterial pneumonia, or such as acute diffuse alveolitis [10] [11] [12] . Abscess and cavity formation have been described, as well as large pleural effusions. Also cases of fulminant evolution into diffuse interstitial fibrosis have been reported [13] [14] [15] [16] [17] [18] [19] . Underlying diseases such as cancer, diabetes, chronic heart disease, and similar conditions may result in a complicated course of the M.
pneumoniae infection [14, 20, 21] .
Concomitant viral infections, especially such that may cause an acute immune suppression, have been reported in up to 18 percent of M. pneumoniae-diseased patients [8] . Caution should be exercised when the serodiagnosis of a viral infection is made during an M. pneumoniae infection, because of the non-specific B-cell mitogenic potency of this organism [22] , a potency which it shares with some viruses. If such mixed infections do occur frequently, it may be difficult to determine whether extrapulmonary symptoms are caused by one or the other infection, or whether both may have mutually complicated the course of illness.
In the acute phase of an M. pneumoniae infection, blood lymphocytes may show a decreased response to PPD in vitro, as shown by Biberfeld and Sterner [23] . This depression of cell-mediated immunity was shown by Mogensen and co-workers [24] to be active also against other microbial antigens like Escherichia coli, Staphylococcus aureus, Bordetella pertussis, and Candida albicans. These findings may be relevant to M. pneumoniae disease complicated by other infections.
Reports on fatal cases are relatively few, but they will probably increase with the growing acknowledgement of severe, unusual, and complicated courses of the disease. To my knowledge, 20 fatal cases have been described in more or less detail in the literature [4, 18, 19, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] , and additional fatal cases have been mentioned in other contexts. The overall impression is that, in addition to the pneumonia, manifestations from other organ systems contributed to the fatal outcome of the M. pneumoniae disease. In five of the 20 10.8 percent had symptoms from the skin and/or mucous membranes, and 7 percent had symptoms from the CNS. The incidence of cases with these extrapulmonary symptoms in each trimester occurred in rather close parallel to the incidence of all seropositive specimens received during the period (Fig. 1) tion. Although 18 of the cases occurred in the high-incidence year 1975, the period was too short for an epidemiological evaluation [39] . Neurological complications have been described in seven of 102 patients hospitalized with a M. pneumoniae infection [4] while the corresponding Finnish figures were 4.8 percent of 560 patients [8] . In a prospective study we found among patients with acute, febrile, non-bacterial CNS affection 5 percent who had serological evidence of a current M. pneumoniae infection [7] .
Cardiac symptoms during M. pneumoniae disease may be more common when looked for as described by Sands and co-workers [40] who found both light and severe cases of carditis in 8.5 percent of hospitalized M. pneumoniae-infected patients. Ponka [9] reported that 4.5 percent of 560 patients with M. pneumoniae infection had carditis, and his epidemiological data point to an etiological role of this mycoplasma. Carre and co-workers [41] advance the hypothesis that M. pneumoniae infection may reveal or aggravate a latent coronary affection. This association was not confirmed in a recent paper by Ponka [42] .
Other non-respiratory tract symptoms seen during M. pneumoniae disease include those from the gastrointestinal tract. Mardh and Ursing [31] have described six cases of pancreatitis following pneumonia due to this infection. Diabetes mellitus developed in two of these, and one case was fatal. In this context it should be noted that Finnish workers have questioned the specificity of CF antibodies to M.
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Quarterly number ot anti-M.pneum. positive and cold-aggi. positive sera pneumoniae in acute pancreatitis [43] . Hematological symptoms in M. pneumoniae disease are rare. Both hemolytic anemia and disturbance of coagulation mechanism have been reported. Signs of disseminated intravascular coagulation have been described, especially in fatal cases. Also arthritis is a rare complication in M. pneumoniae disease [1] [2] [3] 8] .
PATHOGENESIS OF EXTRAPULMONARY MANIFESTATIONS: OBSERVATIONS AND EXPERIMENTAL DATA The extrapulmonary manifestations of M. pneumoniae disease may be a result of the presence of the pathogen in the target organ or organ system. The paucity of reports on isolation of M. pneumoniae from skin eruptions and CNS favors the hypothesis of an indirect effect of the microorganism in most cases [44] [45] [46] [47] . So far, however, no neurotoxin has been demonstrated for this mycoplasma. In several cases a tendency to hypercoagulation has been reported, and intravascular clotting in the CNS cannot be excluded as a pathogenic mechanism [8] .
The variety of neurological clinical pictures which may be seen in M. pneumoniaeinfected patients, both with and without respiratory tract symptoms, and the different time relation to onset of illness and to antibody development may give the impression that more than one mechanism is operating [7] . The possibility of an indirect immune mechanism was advanced when Biberfeld found complementfixing (CF) antibodies to brain tissue antigen in patients with M. pneumoniae infection. However, not all patients had neurological manifestations [48] . In a prospective study of patients with neurological symptoms, we found CF antibodies to brain antigen at a high titer in three of ten patients with a current M. pneumoniae infection, while in 82 neurological patients without evidence of this infection no antibodies to brain were detected [7] .
By investigation of sera from more than 100 patients with M. pneumoniae infection, we found that CF antibodies to brain tissue antigen were present mainly together with high titer CF antibodies to M. pneumoniae. When two matched groups of M. pneumoniae patients were compared, selected in twos by the same anti-M. pneumoniae titer, one with and one without neurological symptoms, antibodies to brain were found significantly more often among the neurological patients (Table 1) [39] .
We fractionated sera by density gradient ultracentrifugation and tested the IgM and IgG classes for antibodies to brain tissue and to M. pneumoniae. In two of four [39] . This partial cross-reaction between antigens of human brain and M. pneumoniae has also been shown by Biberfeld [2] , and it could be further demonstrated when the antigens were used as immunogens in rabbits. As shown in Table 3 , subcutaneous injections of human brain tissue with adjuvant gave rise to [39] . The pathogenic role of these antibodies is not known. This is true also of immune complexes which were demonstrated by Biberfeld and Norberg in the blood during the acute phase of the disease [49] . Another neuropathogenic activity might be one mediated by lymphocytes. When testing blood lymphocytes from patients with M. pneumoniae infection and neurological symptoms Mogensen and Lind [50] found that responses to stimulation with M. pneumoniae antigen in vitro tended to be low or normal in patients who had no pleocytosis in the spinal fluid or no pulmonary infiltrates, while responses were high when either pleocytoses or a pneumonia was present. The high responses were comparable to those obtained with lymphocytes from patients with classical M. pneumoniae pneumonia. The low lymphocyte response which corresponded to lack of lymphocyte accumulations might be due to an effect of antigen-specific suppressor T-lymphocytes.
CONCLUDING REMARKS
The pathogenic mechanisms of the various manifestations and complications of M. pneumoniae disease are still largely unknown. The endeavor to unveil these mechanisms should include attempts to demonstrate the specific antigen in the target organs and tissues. It might prove profitable to investigate further the possible pathogenic role of subpopulations of lymphocytes and their products in M. pneumoniae disease. As a basis of these investigations, the serological criteria of the diagnosis of this disease should be re-evaluated.
